NCT02981784View on ClinicalTrials.gov

Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I

CompletedOBSERVATIONAL

Enrollment

184

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2015

Conditions

Leukemia

Interventions

DRUG

Ponatinib (Iclusig®)

Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.

PROCEDURE

allogeneic stem cell transplantation

Trial Locations (1)

69310

Centre Hospitalier Lyon-Sud, Pierre-Bénite

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER

NCT02981784 - Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I | Biotech Hunter | Biotech Hunter